rational. In a breast cancer model in mice, it has been suggested that neoadjuvant ICI is more effective than adjuvant ICI [3]. In the neoadjuvant setting, there was a stronger systemic antitumor T-cell response with maintenance of tumor specific CD8+ T cells in the blood early after immunotherapy. High levels of CD8+ T cells predicted longterm survival in this mouse model. Moreover, induction of this systemic immune response could lead to immune memory that may prevent metastatic relapse over time. From a clinical perspective, the neoadjuvant strategy has advantages, as we learned from the chemotherapy era. The systemic therapy has better distribution because of the intact vascularization, which may reduce the locoregional tumor extension. There is an early attack microscopic metastatic disease and the effectiveness can be evaluated in vivo with pre-and post-imaging. From a clinical trial perspective, a big advantage is the possibility to study surrogate endpoints. The crucial outcome in this setting is OS, but this endpoint requires many years of follow-up. Here as well, lessons learnt from neoadjuvant chemotherapy followed by surgical resection are of use. Tumor-free lymph nodes and pathological response in the primary tumor have been associated with significantly better outcome. In a dedicated study on the prognostic impact of morphometric tissue analysis of tumor regression, the latter was graded in I: no regression; II: remaining vital tumor tissue 10% (grade IIa) or <10% (grade IIb); and III: no evidence of vital tumor tissue [4]. Patients with tumors of regression grades IIb or III showed significantly longer OS than the others (3-year OS 52% vs 9%, P¼0.02). These findings, however, do not help to select patients for surgery, as they are post-hoc analyses on the resection specimen. Ideally, one should have pre-surgical (pre-hoc analysis) predictors, but the standard clinical restaging with repeat CT after neoadjuvant only is a raw tool for this purpose. Our group first demonstrated that morphometric tissue analysis of mediastinal lymph nodes after induction was a strong prognosticator in that setting [5]. This was then validated in a prospective multi-center setting, using the first video-mediastinoscopy after neoadjuvant chemotherapy [6]. Patients with a grade IIA or III regression (<10% viable tumor) had much better outcome than the others: 5-year OS 43% versus 19%. A recent pilot study evaluated the clinical, pathological, and immunologic effects of short-term neoadjuvant PD-1 blockade in NSCLC [7]. Here again, major pathological response was defined as 10% residual viable tumor on sections of the resected tumor. With this criterion, 45% of the patients had a major pathological response, with clear infiltration of CD8+ T cells in regressing tumors. Moreover, a systemic immune response with T-cells of similar T-cell receptor repertoire as in the tissue were described. Even with its small sample (N¼21), this strategy has a strong mechanistic principle, both in the tumor and on distant sites, and has resulted in a promising surrogate endpoint effect. Whether this will translated in better 5-year OS now needs to be defined in larger multi-center phase 3 trials, several of which are currently started.
rational. In a breast cancer model in mice, it has been suggested that neoadjuvant ICI is more effective than adjuvant ICI [3] . In the neoadjuvant setting, there was a stronger systemic antitumor T-cell response with maintenance of tumor specific CD8+ T cells in the blood early after immunotherapy. High levels of CD8+ T cells predicted longterm survival in this mouse model. Moreover, induction of this systemic immune response could lead to immune memory that may prevent metastatic relapse over time. From a clinical perspective, the neoadjuvant strategy has advantages, as we learned from the chemotherapy era. The systemic therapy has better distribution because of the intact vascularization, which may reduce the locoregional tumor extension. There is an early attack microscopic metastatic disease and the effectiveness can be evaluated in vivo with pre-and post-imaging. From a clinical trial perspective, a big advantage is the possibility to study surrogate endpoints. The crucial outcome in this setting is OS, but this endpoint requires many years of follow-up. Here as well, lessons learnt from neoadjuvant chemotherapy followed by surgical resection are of use. Tumor-free lymph nodes and pathological response in the primary tumor have been associated with significantly better outcome. In a dedicated study on the prognostic impact of morphometric tissue analysis of tumor regression, the latter was graded in I: no regression; II: remaining vital tumor tissue 10% (grade IIa) or <10% (grade IIb); and III: no evidence of vital tumor tissue [4] . Patients with tumors of regression grades IIb or III showed significantly longer OS than the others (3-year OS 52% vs 9%, P¼0.02). These findings, however, do not help to select patients for surgery, as they are post-hoc analyses on the resection specimen. Ideally, one should have pre-surgical (pre-hoc analysis) predictors, but the standard clinical restaging with repeat CT after neoadjuvant only is a raw tool for this purpose. Our group first demonstrated that morphometric tissue analysis of mediastinal lymph nodes after induction was a strong prognosticator in that setting [5] . This was then validated in a prospective multi-center setting, using the first video-mediastinoscopy after neoadjuvant chemotherapy [6] . Patients with a grade IIA or III regression (<10% viable tumor) had much better outcome than the others: 5-year OS 43% versus 19%. A recent pilot study evaluated the clinical, pathological, and immunologic effects of short-term neoadjuvant PD-1 blockade in NSCLC [7] . Here again, major pathological response was defined as 10% residual viable tumor on sections of the resected tumor. With this criterion, 45% of the patients had a major pathological response, with clear infiltration of CD8+ T cells in regressing tumors. Moreover, a systemic immune response with T-cells of similar T-cell receptor repertoire as in the tissue were described. Even with its small sample (N¼21), this strategy has a strong mechanistic principle, both in the tumor and on distant sites, and has resulted in a promising surrogate endpoint effect. Whether this will translated in better 5-year OS now needs to be defined in larger multi-center phase 3 trials, several of which are currently started Although several studies are ongoing, there are until now only two publications describing the effect of preoperative immunotherapy and the intraoperative and the postoperative course of patients with thoracic malignancies. The first study is a publication by Forde and colleagues (1), dealing with patients with resectable lung cancer who received one or two preoperative doses of PD-1-inhibitior Nivolumab. The immunotherapy was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The authors described an acceptable side-effect profile and no delays in surgery. Treatment-related adverse events of any grade occurred in 5 of 22 patients (23%) an only one event was a 3 grades side effect. This was a patient with a pneumonitis who could be resected thereafter that without any complications. The median interval between the administration of the second dose of Nivolumab and surgery was 18 days (range 11 to 29). Twenty of 21 eligible patients underwent a complete resection. The preoperative imaging showed that the majority of the patients (86 %) had stable disease. The other report (2) deals with the safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. This is a retrospective study on 19 patients treated between 2012 and 2016. The majority of them had lung cancer (47 %) followed by metastatic melanoma. Various types of immunotherapeutic agents were used. Anatomic resections (lobectomy or greater) were performed in 11 patients. Complications occurred in 32 % but the majority of them were again only minor. One patients developed postoperative pneumonitis in the contralateral lung approximately 2 weeks after VATS-resection on the other side. In summary, preoperative immunotherapy seems to be applicable with only minor side effects. However, there are only few reports and theoretically other complications might occur. Especially if the side effect spectrum in patients with metastatic disease and immunotherapy is considered (3). Frequent side effects are pneumonitis, hepatitis or even myocarditis. Electronic cigarettes (e-cigarettes) were introduced to the global market in the mid 2000's. While it is common to hear the term "ecigarettes", this label is a broad term referring to a heterogeneous class of devices that differ in shape, size, and functional characteristics. Common features of e-cigarettes include a heating element that heats a propylene glycol and/or vegetable glycerin based solution ("e-liquid" /"e-juice") that contains stabilizers, flavorings and often, nicotine. Numerous flavors are available, including tobacco, menthol, fruit, and sweet flavors. Heating of e-liquids produces an aerosol, which is then inhaled by the user. Due to their relatively short existence, data on the long-term health effects of e-cigarette use are not currently available. In the interim, evidence from animal studies, in vitro and in vivo laboratory studies, observational studies, and small-scale clinical trials may provide important information on the potential harms of e-cigarette use [1] . Many studies conducted on e-cigarettes have focused on the measurement of potentially harmful chemicals that may be produced by these products. Chemicals identified in e-cigarette aerosol include nicotine, tobacco-specific nitrosamines (TSNAs), metals, polycyclic aromatic hydrocarbons (PAHs), volatile organic compounds (VOCs), and aldehydes. Within these classes, there are several respiratory irritants and toxicants, as well as carcinogenic substances linked to the development of respiratory cancers. In our work, we have tested emissions from numerous e-cigarette brands [2] and identified the presence of formaldehyde, acetaldehyde, and acrolein in e-cigarette emissions. Overall, concentrations of toxicants identified in e-cigarette aerosols were 9 to 450 times lower than in tobacco smoke [2] . Concerns have also been raised about the presence of metal particles in e-cigarette aerosol (particularly nickel and chromium, two main elements in heating coils).The inhalation of these metals in larger quantities may cause respiratory diseases, bronchitis, and pneumonia [3], however, these effects have not been definitively elucidated. The size of particulate matter generated from e-cigarettes affects pulmonary nicotine absorption and determines settlement of particulate matter into various parts of the upper or lower airways. There is likely substantial variation across generations of e-cigarette devices, and across brands. Results from laboratory studies indicate that e-cigarettes may expose users to small particles and lower amounts of particulate matter in general. While inhalation of high levels of particulate matter has been linked to greater mortality risk from cardiopulmonary illnesses, the available data indicate that e-cigarette particulate emissions expose users at a level akin to WHO guidelines and are far lower than those of conventional cigarettes. Issues raised about toxicological effects mostly question effects on cells, with a special interest in lung epithelial cells. For instance, many flavorings used in e-cigarettes (e.g. cinnamaldehyde, benaldehyde, diacetyl) are already approved for use in food, yet their impact on respiratory health via repeated inhalation is currently unknown. Several studies have shown that e-cigarette flavorings could lead to lung cell damage (mostly by releasing free radicals) and inflammation in lung tissue [4] . Studies on cytotoxic effects of e-cigarette constituents have also identified negative effects on DNA. In one in vitro research, e-cigarette liquids aerosolized at biologically relevant doses induced increased DNA strand breaks and apoptosis while decreasing survival in both normal epithelial and head and neck squamous cell carcinoma cell lines [5] . Moreover, in experiments conducted by Yu et al.
[6] e-cigarettes aerosol has shown cytotoxic effects on epithelial cell lines and acted as a DNA-breaking agent. Given multiple potential etiologic mechanisms related to incident case development coupled with the long latency period in developing illness, there is currently no definitive evidence to commenting on the role of ecigarettes in increasing lung cancer risk. As an intermediate assessment, cross-sectional biomarker data can be suggestive of possible carcinogen exposures related to cancer development. For instance, Shahab et al. [7] examined a large panel of biomarker data among ecigarette users, cigarette users, and users of both products ("dual users"). The e-cigaretteeonly users had significantly lower metabolite levels for tobacco-specific nitrosamines (TSNAs), particularly NNAL, a metabolite of potent lung carcinogen NNK. Several observational longitudinal studies also showed a substantial reduction in exposure to NNK and several VOCs, including respiratory toxicants like acrolein, acrylamide, acrylonitrile, 1,3-butadiene (human carcinogen), and ethylene oxide among smokers who switched to e-cigarette [8]. Although evidence from biomarker studies are insufficient to evaluate causative mechanisms, but show users of e-cigarettes display lower levels of exposure to biomarkers of lung carcinogens when compared to smokers, such as NNK. Since e-cigarettes have only been on the market for a decade, it is presently not possible to assess all potential long-term harmful effects of e-cigarette use. To date, findings from clinical studies have demonstrated that e-cigarettes are likely less harmful compared to conventional tobacco cigarettes, and any harmful side effects are noticeably milder compared with regular cigarettes. Furthermore, it is also clear that e-cigarette aerosols are not "a harmless water vapor", as claimed by manufacturers and retailers, and potential health effects from vaping may emerge after long-term use. Nicotine Tob Res. 2017; 19:160-167. Keywords: smoking, e-cigarettes, vaping MS15.02 PRO-Electronic Cigarettes: A Cessation Tool K.M. Cummings Medical University of South Carolina, Charleston, SC/US Should clinicians recommend electronic cigarettes (e-cigarettes) to their lung cancer patients who continue to smoke? For many clinicians the answer to this question is a resounding NO WAY. However, I hope to persuade you that there are good reasons why clinicians should strongly consider recommending e-cigarettes to at least some of their patients who smoke. No one disputes the enormous health risks posed by cigarette smoking, or the need to find better treatments to help smokers overcome addiction to cigarettes. In theory, a product that can deliver nicotine like a cigarette without the toxins found in smoke could be used instead of cigarettes would be a welcome invention. E-cigarettes were first introduced into the marketplace in 2003 and were initially promoted as an aid to help smokers to stop smoking. However, concerns have been raised about whether e-cigarettes are an effective cessation aid or if they would actually reduce successful quitting by adult smokers, whether they are safe to use, and if they may be a gateway into smoking for youth. Admittedly, the science is in a state of flux and evolving rapidly. The National Academy of Sciences, Engineering, and Medicine (NASEM) report on the public health consequences of e-cigarettes, and a new evidence review on e-cigarettes and heated tobacco products commissioned by Public Health England (PHE) both come to similar conclusions. Both reports acknowledge that available evidence indicates that e-cigarette use is less risky than use of combustible tobacco cigarettes; that e-cigarettes may be helpful to smokers who are trying to stop smoking cigarettes, and that e-cigarettes should not be used by non-smokers, especially youth. However, both reports also state that e-cigarettes contain constituents that are not inert and are likely to have some negative health effects on their own. Given uncertainties regarding e-cigarettes, clinicians should advise cigarette smokers seeking to stop smoking to use evidencebased, FDA-approved, safe, and effective smoking cessation pharmacotherapies as first-line treatments in preference to e-cigarettes. So why consider e-cigarettes as a treatment option? First, many patients have already tried the evidence based methods and have found them not to be helpful. We need better treatments and e-cigarettes, in theory, might work for some patients. Second, nicotine seeking is the primary motivation for continued smoking so providing addicted smokers with an alternative that delivers nicotine without most of the harmful toxins in smoke makes sense. Nicotine is not the problem, it is the smoke. Ecigarettes are not lit, they do not burn, and do not produce cigarette smoke. Finally, many smokers simply prefer e-cigarettes over other aids to quitting. It is great to have government approved stop smoking treatments, but if smokers are unwilling to use them, they don't do much good. Sales of e-cigarettes have grown exponentially over the past decade, and they have become the most popular quitting aid used by smokers in many countries. For those smokers and ex-smokers who are already using the e-cigarettes, clinicians need to be informed and
